



**Media contact:**  
Ted Ziemann  
ted.ziemann@armisbiopharma.com  
970-576-9694

## **Armis Biopharma Announces Release of Phase 2 Grant Award from the National Institutes of Health**

**August 15, 2022 (Fort Collins, CO)** – Armis Biopharma, Inc. announced that the National Institutes of Health (NIH) recently awarded the company a Phase 2 grant in the amount of \$526,918 to continue to support development of a novel product for skin decontamination after exposure to chemical warfare agents. This is the second phase of a \$2.1 million grant, following successful completion of Phase 1. The project supports the development of Veriox® DECON, a proprietary formulation to provide first responders working on mass-casualty decontamination, an effective, cost-efficient, FDA-approved, fast-acting, field-deployable skin decontamination kit.

With the increasing threat of terrorism, the development of countermeasures for the event of a chemical attack on civilians has become a high priority. Mass casualty events in which chemical warfare agents (CWA) would be employed in an attack on a civilian population are a concrete risk. Because of differences between the military and civilian populations, existing countermeasures may need to be adapted or expanded for use in a civilian population.

“Veriox® DECON offers several advantages over existing decontamination products for mass casualty settings because it can be rapidly dispensed with standard liquid dispensing systems that will allow first responders to quickly decontaminate multiple individuals,” said Ted Ziemann, Chairman and CEO of Armis Biopharma. “Veriox® DECON is also environmentally safe in that it breaks down rapidly into harmless products and demonstrates a better safety and toxicity profile than competitive products.”

Although this project focuses on nerve agent decontamination, Veriox® is also a highly effective antimicrobial agent, having shown excellent efficacy against drug resistant pathogens.

### **About Armis Biopharma**

Armis Biopharma, Inc is a privately held biopharmaceutical company headquartered in Fort Collins, CO that is devoted to developing and commercializing products that are effective in reducing the risk of infectious disease with product development focused on surface disinfection, human and animal wound care, oral care, food safety, and decontaminating chemical and biological warfare agents.

Armis started commercializing products in 2020. Products already in Armis’ product portfolio include VeriFixx® FDA cleared Small Bone Implant, ArmiClenz™ EPA cleared ready to use surface disinfectant, ArmiVet® animal wound wash, ArmiDent™ denture cleaner; ArmiGard™ cleaner for oral devices such as mouth guards and retainers, and ArmiCare® hand sanitizer. Near term future product launches include Turgo® sporicidal disinfectant and VeriCyn™ human wound wash, expected in 2023.

For more information about Armis, please visit [www.armisbiopharma.com](http://www.armisbiopharma.com).

General questions should be addressed to [info@armisbiopharma.com](mailto:info@armisbiopharma.com).